What Rubius Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Appelhans Dannielle | CEO and President | Feb 24 | Open-market sale · S | −10,385 | $0.13 | −$1.32K | 0 |
| Cagnoni Pablo J | Director | Feb 01 | Sale for tax withholding · S | −8,448 | $0.25 | −$2.11K | 66,082 |
| Appelhans Dannielle | CEO and President | Feb 01 | Sale for tax withholding · S | −3,878 | $0.25 | −$970 | 10,385 |
| Cagnoni Pablo J | Director | Jan 31 | Sale for tax withholding · S | −7,240 | $0.24 | −$1.74K | 74,530 |
| Cagnoni Pablo J | Director | Jan 31 | Exercise / conversion · M | +25,000 | — | — | 81,770 |
| Appelhans Dannielle | CEO and President | Jan 31 | Exercise / conversion · M | +7,500 | — | — | 14,263 |
| Turka Laurence A. | Chief Scientific Officer | Jan 31 | Sale for tax withholding · S | −2,593 | $0.24 | −$622 | 18,391 |
| Turka Laurence A. | Chief Scientific Officer | Jan 31 | Exercise / conversion · M | +8,625 | — | — | 20,984 |
| Cagnoni Pablo J | Director | Jan 29 | Exercise / conversion · M | +21,250 | — | — | 56,770 |
| Turka Laurence A. | Chief Scientific Officer | Jan 29 | Exercise / conversion · M | +7,438 | — | — | 12,359 |
| Appelhans Dannielle | Chief Operating Officer | Aug 10 | Sale for tax withholding · S | −5,737 | $0.80 | −$4.59K | 6,763 |
| Appelhans Dannielle | Chief Operating Officer | Aug 09 | Exercise / conversion · M | +12,500 | — | — | 12,500 |
| Epstein David R | Director | Apr 21 | Open-market buy · P | +30,000 | $1.44 | +$43.3K | 4,720,012 |
| Cagnoni Pablo J | CEO and President | Feb 01 | Sale for tax withholding · S | −6,730 | $6.57 | −$44.2K | 35,520 |
| Keson-Brookes Maiken | CLO & Corp. Secretary | Feb 01 | Sale for tax withholding · S | −2,732 | $6.57 | −$18K | 5,343 |
| Turka Laurence A. | Chief Scientific Officer | Feb 01 | Sale for tax withholding · S | −2,517 | $6.57 | −$16.5K | 4,921 |
| Cagnoni Pablo J | CEO and President | Jan 29 | Exercise / conversion · M | +21,250 | — | — | 42,250 |
| Keson-Brookes Maiken | CLO & Corp. Secretary | Jan 29 | Exercise / conversion · M | +8,075 | — | — | 8,075 |
| Turka Laurence A. | Chief Scientific Officer | Jan 29 | Exercise / conversion · M | +7,438 | — | — | 7,438 |
| Cagnoni Pablo J | CEO and President | Jun 16 | Gift · G | −2,200 | — | — | 29,320 |
Loading...
